RT Journal Article
SR Electronic
T1 Ad26.COV2.S priming provides a solid immunological base for mRNA-based COVID-19 booster vaccination
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.07.15.22277639
DO 10.1101/2022.07.15.22277639
A1 Geers, Daryl
A1 Sablerolles, Roos S.G.
A1 van Baarle, Debbie
A1 Kootstra, Neeltje A.
A1 Rietdijk, Wim J.R.
A1 Schmitz, Katharina S.
A1 Bogers, Susanne
A1 Gommers, Lennert
A1 Nieuwkoop, Nella J.
A1 van Dijk, Laura L.A.
A1 van Haren, Eva
A1 Lafeber, Melvin
A1 Dalm, Virgil A.S.H.
A1 Goorhuis, Abraham
A1 Postma, Douwe F.
A1 Visser, Leo G.
A1 Huckriede, Anke L.W.
A1 Sette, Alessandro
A1 Grifoni, Alba
A1 de Swart, Rik L.
A1 Koopmans, Marion P.G.
A1 van der Kuy, P. Hugo M.
A1 GeurtsvanKessel, Corine H.
A1 de Vries, Rory D.
A1 ,
YR 2022
UL http://medrxiv.org/content/early/2022/07/18/2022.07.15.22277639.abstract
AB A large proportion of the global population received a single dose of the Ad26.COV2.S coronavirus disease-2019 (COVID-19) vaccine as priming vaccination, which was shown to provide protection against moderate to severe COVID-19. However, the emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants that harbor immune-evasive mutations in the spike protein led to the recommendation of booster vaccinations after Ad26.COV2.S priming. Recent studies showed that heterologous booster vaccination with an mRNA-based vaccine following Ad26.COV2.S priming leads to high antibody levels. However, how heterologous booster vaccination affects other functional aspects of the immune response remains unknown. Here, we performed immunological profiling on samples obtained from Ad26.COV2.S-vaccinated individuals before and after a homologous (Ad26.COV2.S) or heterologous (mRNA-1273 or BNT162b2) booster vaccination. Both homologous and heterologous booster vaccination increased antibodies with multiple functionalities towards ancestral SARS-CoV-2, the Delta and Omicron BA.1 variants. Especially, mRNA-based booster vaccination induced high levels of neutralizing antibodies and antibodies with various Fc-mediated effector functions such as antibody-dependent cellular cytotoxicity and phagocytosis. In contrast, T cell responses were similar in magnitude following homologous or heterologous booster vaccination, and retained functionality towards Delta and Omicron BA.1. However, only heterologous booster vaccination with an mRNA-based vaccine led to the expansion of SARS-CoV-2-specific T cell clones, without an increase in the breadth of the T cell repertoire as assessed by T cell receptor sequencing. In conclusion, we show that Ad26.COV2.S priming vaccination provides a solid immunological base for heterologous boosting with an mRNA-based COVID-19 vaccine, increasing humoral and cellular responses targeting newly emerging variants of concern.One sentence summary Ad26.COV2.S priming provides a solid immunological base for extension of cellular and humoral immune responses following an mRNA-based booster.Competing Interest StatementA.S. is a consultant for Gritstone Bio, Flow Pharma, ImmunoScape, Moderna, AstraZeneca, Avalia, Fortress, Repertoire, Gilead, Gerson Lehrman Group, RiverVest, MedaCorp, and Guggenheim. LJI has filed for patent protection for various aspects of T cell epitope and vaccine design work. The other authors declare that they have no competing interests.Clinical TrialNCT04927936Funding StatementThis work was financially supported by the Netherlands Organization for Health Research and Development (ZONMW) grant agreement 10430072110001 to R.D.d.V., C.G.v.K., P.H.M.v.d.K., R.S.G.S, W.J.R.R., V.A.S.H.D., D.v.B., N.A.K., A.G., D.F.P., L.G.V., A.L.W.H., M.P.G.K. D.G., L.G., R.L.d.S. and R.D.d.V. are additionally supported by the Health∼Holland grant EMCLHS20017 co funded by the PPP Allowance made available by the Health∼Holland, Top Sector Life Sciences & Health, to stimulate public private partnerships. A.G. and A.S. received Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93021C00016 to A.S.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The SWITCH trial is a single-(participant)-blinded, multi-center, randomized controlled trial among HCWs without severe comorbidities performed in four academic hospitals in the Netherlands (Amsterdam University Medical Center, Erasmus University Medical Center, Leiden University Medical Center, and University Medical Center Groningen), according to the previously described protocol 56. The trial adheres to the principles of the Declaration of Helsinki and was approved by the Medical Research Ethics Committee from Erasmus Medical Center (MEC 2021-0132) and the local review boards of participating centers. All participants provided written informed consent before enrollment.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data needed to evaluate the conclusions in the manuscript is present in the main or the supplementary materials. This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. This license does not apply to figures/photos/artwork or other content included in the article that is credited to a third party; obtain authorization from the rights holder before using such material.